Navigation Links
5 more pharmaceutical companies join NIH initiative to speed therapeutic discovery
Date:6/12/2012

Five additional pharmaceutical companies have joined a National Institutes of Health-led effort to help scientists research promising new treatments for patients. Funding and molecular compound information is available now for the initial phase of the recently unveiled Discovering New Therapeutic Uses for Existing Molecules program. This NIH-industry collaboration will match researchers with 58 compounds to test ideas for new therapeutic uses. Since the launch of the program last month, the total number of compounds the companies are making available has more than doubled.

Abbott, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Pharmaceutical Research & Development, L.L.C., and Sanofi have joined Pfizer, AstraZeneca, and Eli Lilly and Company in this innovative approach to research.

The NIH's new National Center for Advancing Translational Sciences (NCATS) created the Therapeutics Discovery program to help re-engineer the research pipeline. By crowdsourcing compounds that already have cleared several key steps in the development process, including safety testing in humans, scientists nationwide have the opportunity to contribute their expertise to advancing these resources for new disease therapies.

The eight participating companies will provide their compounds and related data, which were determined by the NIH to meet specific eligibility criteria. For example, each compound must have advanced to clinical studies but been unsuccessful in its original therapeutic indication or not pursued for business reasons. Preliminary information about the compounds, including mechanism of action, route of administration, and any limitations in use based on safety and tolerability, are available at http://ncats.nih.gov/therapeutics-directory.html.

"Each company participating in this innovative collaboration has made substantial research and development investments to advance these compounds to the point where they can be used in clinical studies," said Kathy L. Hudson, Ph.D., NCATS acting deputy director. "If researchers funded through this effort can demonstrate new uses for the compounds, they could significantly reduce the amount of time it takes to get a treatment to patients in need."

For the pilot phase of the program, in fiscal year 2013, NCATS will provide up to $20 million to fund two- to three-year staged, cooperative agreement research grants. If specific milestones are met, funded researchers will conduct pre-clinical validation and clinical feasibility studies in the first stage, and proof-of-concept clinical trials in the second stage, to test whether one of the compounds may be effective against a previously unexplored disease target. The pilot phase also is intended to test the utility of the newly created template agreements by reducing the negotiation time that otherwise could delay the research.


'/>"/>

Contact: Bobbi Gardner
gardnerbw@mail.nih.gov
301-443-9919
NIH/National Center for Research Resources
Source:Eurekalert

Related medicine news :

1. Nobel laureate to keynote international pharmaceutical conference at URI
2. MSU invention could help pharmaceutical industry save money
3. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
4. Georgia Tech launches HomeLab to help companies evaluate home health technologies
5. Kudos for 3 NJIT Enterprise Development Center high-tech companies
6. New initiative aims to increase mobility for disabled children worldwide
7. National initiative launched to change the way biology departments approach undergraduate education
8. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
9. U.S. Spends Too Little on Public Health Initiatives: Report
10. Program to coordinate regional systems to speed heart attack care
11. Advanced genetic screening method may speed vaccine development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original campaign ... crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget to ... fidget toy to the market that was made of superior quality and wouldn’t break ...
(Date:5/26/2017)... ... , ... Silver Birch of Hammond, a new assisted lifestyle community, has welcomed ... of land at 5620 Sohl Avenue in Hammond, serves older adults who need some ... and one-bedroom apartments. Each of the private apartments at Silver Birch features a kitchenette, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral ... new, informational blog post on insurance options. If a Bay Area patient has to ... save time and money. Visiting an in-network provider for a second opinion can ensure ...
(Date:5/26/2017)... ... ... to the Cross”: the personal journey of Bob Massey and his faith in the Lord. ... and Margaret Massey. Bob Massey is small in stature but big in character. ... love for others is apparent in all of his life decisions. , “I’m in ...
(Date:5/26/2017)... ... ... What Happened in the Garden of Eden”: retells the stories of three Bible figures in ... published author, Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. ... At six, they moved to Dayton, Ohio, where Penny graduated high school. At ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... 25, 2017  In response to the opioid epidemic ... Relief is working with Pfizer to make up to ... cost to community health centers, free and charitable clinics, ... "Pfizer has a long-standing commitment to improving ... patient safety through educational activities," said Caroline Roan ...
(Date:5/23/2017)... Calif. , May 23, 2017  Leaf ... most innovative medical devices for pressure ulcer prevention, ... the American Association of Critical Care Nurses, National ... May 22-25. The Leaf Patient Monitoring ... specifically for the hospital environment.  The system seamlessly ...
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
Breaking Medicine Technology: